Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

NCT05822609 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide can help people with type 1 diabetes and diabetic kidney disease.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 60 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2024-04 · est. completion 2026-06

Where 4 sites · Canada, United States

What this study is testing ClinicalTrials.gov NCT05822609 ↗

Description as written by the study sponsor.

The primary objective of this study is to determine the effects of semaglutide on kidney oxygenation and function in type 1 diabetes. The secondary objective is to determine the glycemic effects and safety of semaglutide in type 1 diabetes.

Treatments tested

Semaglutide Drug

1.0 mg
Placebo Other

Placebo

Main thing measured	Change in kidney cortical relaxation rates (R2*)
Sponsor	University of Washington
Conditions studied	Diabetic Kidney Disease, Type 1 Diabetes
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05822609 ↗